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Abstract
In Parkinson's disease, dopamine- containing nigrostriatal neurons undergo pro-
found degeneration. Tyrosine hydroxylase (TH) is the rate- limiting enzyme in dopa-
mine biosynthesis. TH increases in vitro formation of reactive oxygen species, and 
previous animal studies have reported links between cytosolic dopamine build- up 
and oxidative stress. To examine effects of increased TH activity in catecholamin-
ergic neurons in vivo, we generated TH- over- expressing mice (TH- HI) using a BAC- 
transgenic approach that results in over- expression of TH with endogenous patterns 
of expression. The transgenic mice were characterized by western blot, qPCR, and 
immunohistochemistry. Tissue contents of dopamine, its metabolites, and markers 
of oxidative stress were evaluated. TH- HI mice had a 3- fold increase in total and 
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1  | INTRODUC TION
The neurochemical hallmark of Parkinson's disease is depletion of 
the catecholamine dopamine in the nigrostriatal system, particu-
larly in the putamen (Kish et al. 1988). By the time the characteris-
tic motor symptoms manifest clinically, it is likely that a substantial 
proportion of striatal dopaminergic terminals have already been lost 
(Dalle- Donne et al. 2008). The dropout of midbrain substantia nigra 
neurons seems often to be preceded by comparable degeneration of 
noradrenergic neurons in the pontine locus coeruleus (Del Tredici & 
Braak, 2013), which might contribute to pre- motor symptoms (Braak 
et al. 2003; Darvas et al. 2014; Fahn, 2003).
Oxidative stress is widely recognized as a contributor to the 
pathogenesis of idiopathic Parkinson's disease; however, why 
catecholaminergic neurons are especially susceptible remains 
incompletely understood. Many factors may underlie the prefer-
ential vulnerability of catecholamine neurons, including patterns 
of alpha(α)- synuclein aggregation and spread; mitochondrial dys-
function; an extensive axonal arbor, particularly characteristic of 
substantia nigra cells; and cell- or region- specific characteristics of 
cell signalling, including an increasing dependency on calcium chan-
nels, which can increase mitochondrial stress (Blesa et al. 2015; 
Bolam & Pissadaki, 2012; Puspita et al. 2017; Ricke et al. 2020; 
Surmeier, 2007, 2018; Surmeier et al. 2017). Another specific source 
of vulnerability may relate to autotoxicity resulting from metabolites 
of the catecholamines (Goldstein et al. 2014; Masato et al. 2019; 
Miyazaki & Asanuma, 2008). Testing this notion in vivo, however, 
has been a difficult challenge that few studies have tackled.
The rate- limiting enzyme in catecholamine biosynthesis is tyro-
sine hydroxylase (TH). During catecholamine synthesis, small amounts 
of reactive oxygen species (ROS) are generated (Adams et al. 1997; 
Haavik et al. 1997; Kostyn et al. 2020). Activity of TH is modulated 
by phosphorylation of 3 main serine (Ser- ) residues on its amino 
terminus: Ser19, Ser31, and Ser40 (Daubner et al. 2011; Dunkley & 
Dickson, 2019). The predominant source of TH activation is phos-
phorylation at Ser40, chiefly mediated by cyclic AMP- dependent 
protein kinase A (PKA) (Lehmann et al. 2006; Salvatore et al. 2001). 
Phosphorylation of TH at Ser31 by extracellular signal- related protein 
kinases I and II (ERKI and II) is also believed to directly promote en-
zymatic activity, possibly with a greater role in somatodendritic 
compartments of dopaminergic cells (Salvatore, 2014; Salvatore 
et al. 2016, 2018). In contrast, phosphorylation of Ser19, primarily me-
diated by calmodulin- stimulated protein kinase II (CaMK II), is believed 
to facilitate enzymatic activity indirectly by inducing a conformational 
change and increasing phosphorylation at Ser40 and Ser31 (Haycock 
et al. 1998; Lindgren et al. 2000). By releasing the enzyme from end- 
point inhibition and returning it to its activate state, phosphorylation 
of TH plays a direct role in the rate of catecholamine synthesis and 
bioavailability (Daubner et al. 2011; Dunkley et al. 2004).
Protein phosphatase 2A (PP2A) is the main phosphatase respon-
sible for dephosphorylating TH and regulating its activity (Haavik 
et al. 1989; Peng et al. 2005). In addition, α- synuclein also nega-
tively regulates the activity of TH, directly and indirectly, by activat-
ing PP2A (Hua et al. 2015; Liu et al. 2008; Peng et al. 2005; Perez 
et al. 2002; Qu et al. 2018). However, α- synuclein phosphorylated 
at Ser129— a major constituent of insoluble α- synuclein aggregates 
(Arawaka et al. 2017; Walker et al. 2013; Zhou et al. 2011)— has a 
limited ability to inhibit TH activity (Lou et al. 2010; Wu et al. 2011) 
and has been linked to dopamine dysregulation (Alerte et al. 2008). 
Increased levels of Ser129 phosphorylation have been associated 
with diminished PP2A, in part because PP2A is also responsible for 
dephosphorylating α- synuclein (Liu et al. 2015; Park et al. 2016). 
Recent studies have shown that the relationship between reduced 
PP2A and α- synuclein Ser129 phosphorylation is one of positive 
feedback, with aggregated or phosphorylated α- synuclein further 
reducing PP2A function (Chen et al. 2016; Liu et al. 2015; Tian 
et al. 2018) and TH regulation (Farrell et al. 2014).
Studies in transgenic models show that increased TH activity and 
elevated ROS can result from diminished regulation placed on the 
enzyme. In Drosophilia and C. elegans, dysfunctional α- synuclein has 
been reported to increase levels of phosphorylated TH and elevate 
dopamine levels, ultimately leading to oxidative stress and neuro-
degeneration (Locke et al. 2008; Park et al. 2007). Similarly, mice 
with mutated or aggregated α- synuclein show increased levels of 
TH activity and behavioural impairment attributed to catecholamine 
dysregulation (Alerte et al. 2008; Farrell et al. 2014). Therefore, 
Lundbeckfonden, Grant/Award Number: 
R223- 2015- 4222 and R248- 2016- 2518 phosphorylated TH levels and an increased rate of dopamine synthesis. Coincident 
with elevated dopamine turnover, TH- HI mice showed increased striatal production 
of H2O2 and reduced glutathione levels. In addition, TH- HI mice had elevated stri-
atal levels of the neurotoxic dopamine metabolites 3,4- dihydroxyphenylacetaldehyde 
and 5- S- cysteinyl- dopamine and were more susceptible than wild- type mice to the 
effects of amphetamine and methamphetamine. These results demonstrate that in-
creased TH alone is sufficient to produce oxidative stress in vivo, build up autotoxic 
dopamine metabolites, and augment toxicity.
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increased activity of TH, in concert with other changes, could pres-
ent a source of oxidative stress unique to catecholamine neurons 
(Alerte et al. 2008; Chen et al. 2016; Hua et al. 2015; Liu et al. 2015; 
Lou et al. 2010; Park et al. 2016; Peng et al. 2005).
ROS resulting from the accumulation of cytosolic dopamine may 
represent an additional source of oxidative stress in cells with increased 
synthetic activity (Chen et al. 2008; Stansley & Yamamoto, 2013). 
Ordinarily, cytosolic dopamine levels are kept very low because of avid 
uptake into vesicles via the type 2 vesicular monoamine transporter 
(VMAT2). Unsequestered dopamine undergoes metabolism by mono-
amine oxidase (MAO), which generates hydrogen peroxide (H2O2) 
as well as the catecholaldehyde 3,4- dihydroxyphenylacetaldehyde 
(DOPAL), a highly reactive intermediate metabolite (Goldstein 
et al. 2016; Graham, 1978; Hermida- Ameijeiras et al. 2004). 
DOPAL is metabolized by aldehyde dehydrogenase (ALDH) to form 
3,4- dihydroxyphenylacetic acid (DOPAC), which rapidly exits the cells 
(Lamensdorf et al. 2000).
According to the catecholaldehyde hypothesis, DOPAL can play 
a role in the pathogenesis of Parkinson's disease (Casida et al. 2014; 
Fitzmaurice et al. 2013; Goldstein et al. 2016; Panneton et al. 2010; 
Wey et al. 2012), especially via modifications of cytosolic proteins 
such as α- synuclein (Jinsmaa et al. ,2018, 2020). DOPAL has been 
shown to promote oligomerization of α- synuclein by covalent mod-
ifications of lysine residues (Burke et al. 2008; Follmer et al. 2015), 
and DOPAL- induced α- synuclein oligomers impede vesicular func-
tions (Plotegher et al. 2017), potentially setting the stage for a vicious 
pathophysiological cycle. Moreover, in the setting of divalent metal 
cations, DOPAL can react with H2O2 to produce extremely toxic 
hydroxyl radicals (Li et al. 2001; Werner- Allen et al. 2017). Finally, 
DOPAL spontaneously oxidizes to DOPAL- quinone, in the process 
generating superoxide radicals (Anderson et al. 2011; Werner- Allen 
et al. 2017).
Cytosolic dopamine can also undergo spontaneous oxidation 
to produce dopamine- quinone and then a variety of potentially 
toxic downstream products such as aminochrome, salsolinols, 
and 5- S- cysteinyl- dopamine (Cys- DA) (Chen et al. 2008; Hastings 
et al. 1996; Miyazaki & Asanuma, 2008; Montine et al. 1997; Segura- 
Aguilar et al. 2014; Stansley & Yamamoto, 2013; Storch et al. 2002). 
Dopamine can form quinoprotein adducts with α- synuclein (Bisaglia 
et al. 2010), although in this regard DOPAL is more potent (Jinsmaa 
et al. 2020).
Based on previous studies, increased activity of TH has the capac-
ity to facilitate the development of oxidative stress via two main pro-
cesses. First, ROS can be generated during catecholamine synthesis, 
previously shown in vitro; and second, elevated synthesis may result 
in increased levels of cytosolic dopamine, which promotes oxidative 
stress through metabolic and spontaneous oxidation. To evaluate 
the specific effect of elevated TH in vivo, we developed a novel line 
of transgenic mice over- expressing functional TH. We hypothesized 
that an increase in the enzymatic activity of TH would increase oxi-
dative stress and augment endogenous levels of both enzymatic and 
spontaneous oxidation products of dopamine. TH over- expressing 
mice have been produced previously (Kaneda et al. 1991); however, 
our model is the first to achieve functional over- expression of TH 
and increased dopamine synthesis that are restricted to endogenous 
catecholaminergic regions.
2  | MATERIAL S AND METHODS
Experiments were conducted in adult mice (male and female), 
3– 5 months of age (for experimental design, see Figure 1). Mice were 
housed on a 12- hr light– dark cycle, with food and water provided 
ad libitum. No randomization was performed to allocate subjects in 
the study. Mice within a genotype were allocated arbitrarily to the 
experimental groups such that each group contained comparable 
numbers of males and females. Group sizes were based on previ-
ous work (Masoud et al. 2015; Salahpour et al. 2008). In most cases, 
the experimenter was not aware of the genotype of the mice until 
the point of statistical analysis. Western blots were an exception, as 
these were loaded such that samples within a genotype or treatment 
group neighboured each other on the blot.
A total of 332 mice were used for this study, inclusive of all ex-
perimental groups and genotypes. Effort was made to minimize anx-
iety and suffering by habituating animals to behavioural suites, and 
ensuring that mice were accustomed to the experimenters' touch 
and scent.
Anaesthesia (avertin) was verified by the toe- pinch and eye- 
brush methods, and by observing a depression in respiratory rate 
(i.e. that breathing had appreciably slowed). Shortly in advance 
of experiments requiring anaesthesia, a 20- mL stock volume 
of avertin was prepared: in a 1.5- mL Eppendorf tube, 0.5 ml of 
2- methyl- 2- butanol (Sigma, cat. no. 152463) was added to 0.25 g of 
2,2,2- tribromoethanol (Sigma, cat. no. T48402). The solution was 
heated slightly (37– 40℃) and mixed well. The solution was added 
slowly to sterile ddH2O, and topped to a total volume of 20 ml; the 
stock solution (1.25 g/ml) was then sterilized through a 0.22- μm 
filter. Aliquots were stored in the dark at 4℃, and prepared fresh 
weekly; aliquots were thawed in the dark before use. Mice were in-
jected intraperitoneally at a dose of 200 mg/kg.
Euthanasia was performed with the guidance and approval of 
the Animal Care Committee. Procedures conformed to the recom-
mendations of the Canadian Council on Animal Care, with proto-
cols reviewed and approved by the University of Toronto Faculty of 
Medicine and Pharmacy Animal Care Committee (protocol number 
20011466).
2.1 | Production of TH- over- expressing mice using 
BAC transgenesis
Mice over- expressing TH were created by bacterial artificial chro-
mosome (BAC) transgenesis using an artificial chromosome that 
contains the murine Th locus as well as approximately 90 kb of 
genomic DNA upstream and downstream of the gene (RP23- 
350E13, Genome Sciences), using previously described methods 
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(Lohr et al. 2014; Salahpour et al. 2008). Because BACs often contain 
the endogenous promotor for a gene of interest, gene expression is 
restricted to regions that endogenously express it. Bacterial colonies 
were grown on a chloramphenicol- spiked lysogeny broth (LB) agar 
plate, and single colonies were randomly selected for growth in 
liquid LB media (12.5 µg/ml chloramphenicol). The colonies were 
F I G U R E  1   Experimental design. A bacterial artificial chromosome (BAC) carrying the tyrosine hydroxylase gene (Th, 7.19Kb) as well as 
103 Kb and 90 Kb of genomic DNA upstream and downstream of the gene was selected (RP23- 350E13). Bacterial colonies were grown 
on a chloramphenicol- spiked lysogeny broth (LB) agar plate, and single colonies were randomly selected for growth in liquid LB media 
(12.5 µg/ml chloramphenicol). The colonies were verified by PCR- based genotyping using primers that amplify a sequence overlapping the 
BAC vector and the Th gene. The BAC DNA was isolated and purified using a NucleoBond BAC 100 preparation kit. After resuspension, 
the DNA preparation was inserted into fertilized oocytes using pronuclear microinjection, then implanted into a pseudopregnant mother. 
Of the first litter born to her, there were four pups identified as transgenic. A pup that had six total copies of the Th gene (i.e. 4 transgenic 
copies) was used as the founder to a novel line of TH over- expressing mice, 'TH- HI'. From this mouse, a colony was established. Adult mice 
approximately 3– 5 months of age were used for further studies. These experiments fell into three main groups: those that characterized the 
novel TH- HI mouse line (gene, mRNA and protein analyses); those that analysed tissue content of dopamine, its metabolites, and markers of 
oxidative stress; and those that assessed the locomotor response to compounds known to affect the dopaminergic system, amphetamine, 
and methamphetamine. The number of mice (n) used for each experiment is indicated. Cys- DOPA, 5- S- cysteinyldopa; Cys- DA, 5- S- 
cysteinyldopamine; D1/D2, dopamine receptors type 1 and 2; DA, dopamine; DHPG, 3,4- dihydroxyphenylethylene glycol; DAT, dopamine 
transporter; DOPAC, 3,4- dihydroxyphenylacetic acid; DOPAL, 3,4- dihydroxyphenylacetaldehyde; L- DOPA, l- 3,4- dihydroxyphenylalanine; 
n, number of mice; NA, noradrenaline; TH, tyrosine hydroxylase; TH- HI, transgenic mice over- expressing tyrosine hydroxylase; VMAT2, 
vesicular monoamine transporter 2; VMAT- kd, VMAT2- knockdown mice; WT, wild- type mice
preparation of bacterial artifical chromosome
Pronuclear injection and implantation
into pseudopregnant female 
103 Kb
Th ( 7.19 Kb)
90 Kb
4 transgenic pups born
Presence of Th transgene determined for all pups
One mouse with 4 additional copies of Th
chosen as colony founder to ‘TH-HI’ line 
colony established
characterisation of TH-HI mice
(gene and protein analyses)
total TH genomic copy number: 
WT=5, TH-HI=5
TH mRNA: WT=8, TH-HI=7
protein analysis:
midbrain and striatal TH: WT=6, TH-HI=6
midbrain and striatal DAT: WT=6, TH-HI=6
locus coeruleus TH: WT=4, TH-HI=5 
striatal phosphoTH ser19: WT=6, TH-HI=6
striatal phosphoTH ser31: WT=4, TH-HI=6
striatal phosphoTH ser40: WT=6, TH-HI=6
striatal VMAT2: WT=5, TH-HI=6, VMAT2-kd=2
peripheral TH: WT=6, TH-HI=5
immunohistochemistry of TH in midbrain, 
striatum and locus coeruleus: n=4 to 6 
per region, per genotype
(representative samples shown)
dopamine, metabolites, 
and markers of oxidative stress
tissue content:
striatal L-DOPA: WT=7, TH-HI=7
striatal DA, DOPAC, DOPAL, Cys-DOPA
and Cys-DA: WT=10, TH-HI=9
cardiac DA, DOPAC, NA, DHPG, DOPAL, 
Cys-DA: WT=12, TH-HI=8
striatal glutathione: WT=14,TH-HI=14, 
reserpine-treated WT=7
striatal H2O2: WT=8, TH-HI=9
Aged 3 - 5 months 
amphetamine and 
methamphetamine challenges
unstimulated locomotor behaviour, 240 min:
WT=12, TH-HI=11
amphetamine challenge (saline, 2.0 mg/kg
or 3.0 mg/kg): n=6-13 per genotype, per
treatment group 
3.0 mg/kg amphetamine with saline or 
NSD-1015 pretreatment: n=5-8 per genotype,
per condition
D1/D2 receptor analyses: WT=4, TH-HI=4
methamphetamine challenge (saline, 
5.0 mg/kg, or 10.0 mg/kg methampehtamine):
n= 5-7 per genotype, per treatment group 
(RP23-350E13)
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verified by PCR- based genotyping using primers that amplify a 
sequence overlapping the BAC vector and the Th gene (forward, 
5’- gaaggctctcaagggcatc; reverse, 5′-­acaggtcaggctctcaggtc).
The BAC DNA was isolated using a NucleoBond BAC 100 prepa-
ration kit (Macherey- Nagel, cat no. 740579) and resuspended in in-
jection buffer (spermine, 0.03 mM; spermidine, 0.07 mM). Pronuclear 
microinjections were performed at the Emory University Transgenic 
Facility. Transgenic positive pups were identified by PCR- based ge-
notyping (5’- aggagctgactgggttgaag; reverse, 5′-­tcgtggcctgttgtgagtag); 
again, primer sequences overlapped the vector and gene sequences, 
thereby differentiating transgenic Th from native Th. Of the F1 
generation, a mouse determined by qPCR to possess 6 total cop-
ies of genomic Th was used as a founder for a transgenic high copy 
line, "TH- HI." Transgenic mice were maintained on a C57Bl/6J 
background.
2.2 | Determination of gene copy number and total 
Th mRNA levels
2.2.1 | Gene copy number
Genomic DNA was isolated from tail biopsy following Proteinase K di-
gestion and isopropanol precipitation (Ballester et al. 2004; Burkhart 
et al. 2002), and cleaned using a chloroform- ammonium acetate wash 
method. Quantitative PCR (qPCR) was used to determine total allelic 
copy number of Th, inclusive of both native alleles and transgenic cop-
ies (Ballester et al. 2004; Shepherd et al. 2009). Amplicons of the Th 
genomic sequence were generated using designed primers (forward: 
5’- caccagtcctgagtttcctatt, reverse: 5’- ctggatcacactccaccatatc) and meas-
ured relative to those of a common reference gene that encodes the 
transferrin receptor (Tfrc; forward: 5’- cagtcatcagggttgcctaata, reverse: 
5’- atcacaacctcaccatgtaact). Relative quantification of Th and Tfrc were 
obtained using the GoTaq® qPCR Master Mix (Promega, cat no. A6002) 
on the Applied Biosystems 7500 Real- Time PCR System. The PCR pro-
tocol used for all reactions was as follows: 2 min at 50℃, 10 min at 95℃, 
40 repeats of 95℃ for 15 s, and 1 min at 60℃. Analysis of gene copy 
number was based upon the 2- ∆∆CT method as previously described 
(Livak & Schmittgen, 2001; Pfaffl, 2001; Schmittgen & Livak, 2008).
2.2.2 | mRNA
Reverse- transcriptase qPCR was also used to determine total levels 
of mRNA on midbrain regions dissected from a 1- mm coronal section 
of brain, which was previously removed and frozen in 2- methybutane 
over dry ice and stored at −80℃ (Hu et al. 2009); 300 ng of RNA 
was used to obtain complementary DNA using SuperScript III 
Reverse Transcriptase (Invitrogen, cat no. 11752- 250) according to 
the manufacturer's instructions. As before, quantification of mRNA 
levels was obtained using the GoTaq® qPCR Master Mix on the 
Applied Biosystems 7500 Real- Time PCR System. To ensure that the 
level of Th mRNA was normalized to the volume of dopaminergic 
cells within the dissected area, Th mRNA levels (forward primer: 
5'- cgggcttctctgaccaggcg; reverse primer: 5'- tggggaattggctcaccctgct) 
were presented as a ratio of the dopamine transporter (DAT), 
Slc6a3, mRNA levels (forward primer: 5'- ggcctgggcctcaacgacac; re-
verse primer: 5'- ggtgcagcacaccacgtccaa). Phosphoglycerate kinase 
1 (Pgk1; forward primer:5'- ggcctttcgacctcacggtgt; reverse primer: 
5'- gtccaccctcatcacgacccg) was used as the reference gene, and relative 
quantification of both targets was obtained using the 2- ∆∆CT method.
2.3 | Western blotting
2.3.1 | Total TH and DAT in the central and 
peripheral systems
Western blots were performed to quantify TH and DAT protein 
expression in the dopaminergic nigrostriatal pathway, using the 
sodium- potassium pump (Na+/K+- ATPase) as a loading control. The 
midbrain (substantia nigra) and striatum were dissected from freshly 
harvested brains, flash- frozen, and mechanically homogenized in 
RIPA buffer [50 mM Tris·HCl, pH 7.4; 150 mM NaCl; 1% Nonidet 
P- 40; 0.5% sodium deoxycholate; 0.1% sodium dodecyl sulphate 
(SDS)] with protease inhibitors (pepstatin A, 5 μg/mL; leupeptin, 
10 μg/mL; aprotinin, 1.5 μg/mL; benzamidine, 0.1 μg/mL; PMSF, 
0.1 mM). Samples were centrifuged at 21,130 g for 15 min to remove 
cellular debris and the supernatant was collected. Protein concen-
trations were determined using a Pierce bicinchoninic acid (BCA) 
assay (Thermo Scientific, cat no. 23225). Samples were prepared 
to the desired loading amount (striatum, 25 μg; midbrain, 60 μg) 
in a solution containing 1× SDS sample buffer (4× solution: 3.4 g 
Tris Base, 8.0 g SDS, 40 ml glycerol in 1 L dH2O, pH 6.8), 0.05% β- 
mercaptoethanol (BME), and RIPA buffer. Preparations were heated 
to 55℃ for 10 min, separated by 10% SDS/PAGE, and wet- transferred 
to polyvinylidene difluoride (PVDF) membranes (FluoroTrans, Pall, 
cat no. CA29301- 856). Membranes were blocked in Li- COR buffer 
for 60 min at room temperature and incubated overnight at 4℃ with 
rat anti- DAT (1:750; Millipore, cat no. MAB369, RRID: AB_2190413) 
and rabbit anti- Na+/K+- ATPase (1:2000; cat no. 3010, RRID: 
AB_2060983) in the same buffer. After washing, protein bands were 
revealed by incubating with the fluorescence- labelled secondary 
antibodies donkey anti- rat IRdye 800CW (1:5,000; Rockland, cat 
no. 612- 732- 120, RRID:AB_220173) and goat anti- rabbit AlexaFluor 
AF680 (1:5,000; Invitrogen, cat no. A21076, RRID: AB_2535736) for 
60 min at room temperature. Without stripping, membranes were 
then blocked a second time in 5% non- fat milk and probed with rab-
bit anti- TH (1:3,000; Millipore, cat no. AB152, RRID: AB_390204) 
overnight at 4℃, which was again revealed with goat anti- rabbit 
AlexaFluor AF680.
Using similar methods, TH protein levels in both central and 
peripheral noradrenergic regions were examined. Tissue from the 
TH- rich locus coeruleus and the adrenal medulla was extracted, pre-
pared, and run as described above (loading 60 μg per sample for the 
locus coeruleus, 20 μg per sample for the adrenal medulla). PVDF 
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membranes were probed for rabbit anti- TH as described above. 
Mouse anti- β- tubulin (1:1,000; Developmental Studies Hybridoma 
Bank, E7) and mouse anti- GAPDH (1:3,000; Sigma, cat no. G8795, 
RRID:AB_1078991) were used as loading controls for the locus coe-
ruleus and adrenal medulla (respectively), and revealed with donkey 
anti- mouse IRdye 800CW (1:5,000; Rockland, cat no. 610- 731- 002, 
RRID: AB_1660943).
2.3.2 | Phosphorylated TH
Levels of TH phosphorylated at serine residues 19, 31, and 40 
were also measured, as a representation of TH in an active con-
formation. In a separate set of experiments, striatal samples were 
quickly dissected, flash- frozen, and homogenized in RIPA con-
taining phosphatase inhibitors (sodium pyrophosphate, 2.5 mM; 
β- glycerophosphate, 1.0 mM; sodium fluoride, 50 mM; sodium or-
thovanadate, 1.0 mM), in addition to the protease inhibitors listed 
above. As before, striatal samples were prepared to the desired 
loading amount of 25 μg, run on a 10% SDS/PAGE gel, and trans-
ferred to PVDF membrane. Membranes were incubated overnight 
at 4℃ in solutions containing rabbit anti- phosphoTH- Ser19 (1:2000; 
PhosphoSolutions, cat no. p1580- 19), rabbit anti- phosphoTH- Ser31 
(1:1,000; PhosphoSolutions, cat no. p1580- 31), or rabbit anti- 
phosphoTH- Ser40 (1:2000; PhosphoSolutions, cat no. p1580- 40). 
Proteins were revealed using goat anti- rabbit AF680 (1:5,000) before 
being stripped, and reprobed using mouse anti- TH (1:2,500; Sigma, 
cat no. T2928, RRID:AB_477569) and mouse anti- GAPDH in 5% non- 
fat milk. These were revealed with donkey anti- mouse IRdye 800CW.
2.3.3 | VMAT2
Levels of VMAT2 were assessed using pre- cast gels and MOPS 
(3- (N- morpholino)propanesulfonic acid) buffers, with rabbit anti- 
VMAT2 antibody (1:10,000, in- house antibody), as previously de-
scribed (Cliburn et al. 2017; Lohr et al. 2014). The VMAT2 protein 
was revealed with goat anti- rabbit 800 (1:5,000; Rockland, cat no. 
611- 131- 002, RRID: AB_1660973) by incubating for 60 min at room 
temperature, and membranes were reprobed for TH and GAPDH as 
above.
For all of the above westerns, proteins were visualized using the 
LiCOR Odyssey system. Densitometric analyses were conducted 
using Image Processing and Analysis in Java (ImageJ) software 
(http://rsb.info.nih.gov/ij/index.html). For full (uncropped) blots, see 
https://osf.io/9q7b5/ ?view_only=c580d 782a7 7d475 984bb 35eb4 
1738279.
2.4 | Radioligand binding
Radioligand binding was used to assess D1 and D2 dopamine recep-
tor levels in the striatum as previously described (Ghisi et al. 2009). 
Striatal tissues were rapidly dissected and homogenized in lysis 
buffer (50 mM Tris– HCl, pH 7.4; 120 mM NaCl; 1 mM EDTA) con-
taining protease inhibitors. The homogenate was centrifuged at 
1,000 g for 10 min (4℃) to remove cellular debris and nuclei, after 
which supernatant was centrifuged at 40,000 g for 20 min (4℃); the 
pellet was then resuspended in lysis buffer and centrifuged again 
under the same conditions. The final pellet was resuspended in assay 
buffer (50 mM Tris– HCl (pH 7.4), 120 mM NaCl, 5 mM KCl, 2 mM 
CaCl2, and 1 mM MgCl2). Protein concentration of membranes was 
determined using BCA protein assay.
For D1 receptor saturation experiments, 50 μl of prepared stri-
atal membranes (1.2 μg/μl) was incubated with 50 μl of 16 nM [3H]- 
SCH23390, a D1 receptor antagonist, as well as 50 μl of 100 mM 
ketanserin, a serotonin receptor antagonist, to prevent radioligand 
binding to these receptors. The reaction was performed in 200 μl of 
assay buffer for 1 hour, at room temperature. In parallel reactions, 
nonspecific binding was measured using non- radiolabelled flupen-
thixol (10 μM), a D1/D2 receptor antagonist. For D2 receptor satu-
ration experiments, 150 μl of prepared striatal membranes (0.5 μg/
μl) was incubated with 50 μl of [3H]- spiperone (3 nM), a D2 receptor 
antagonist. This reaction was performed in 250 μl of assay buffer for 
2 hours at room temperature; non- specific binding was measured in 
parallel using non- radiolabelled haloperidol (6 μM), a D2 antagonist.
All reactions were terminated by filtration over Brandel GF/C 
glass fibre filters and washing with cold assay buffer. Filters were 
incubated overnight in high flash point scintillation cocktail (5 ml, 
Lefko- Fluor). Radioactivity was counted using a liquid scintillation 
counter. Counts of non- specific binding were subtracted from total 
binding to obtain specific [3H]- SCH23390 or [3H]- spiperone bind-
ing, which corresponds to D1 or D2 binding, respectively, and con-
verted to fmol/mg tissue for final results. The experimenter was 
blinded until the point of statistical analyses.
2.5 | Immunohistochemistry
Adult mice were anaesthetized with avertin (200 mg/kg) prior to 
perfusions, and intracardially perfused with phosphate- buffered 
saline (PBS) at a flow rate of 80 ml/h for 2 min, followed by 4% 
paraformaldehyde in PBS for approximately 10 min. The brains 
were removed and stored in 4% paraformaldehyde in PBS over-
night at 4℃, then transferred to a 30% sucrose solution for cryo-
protection for 48 hr at 4℃. Tissues were blocked in freezing media 
HistoPrep (Fisher Chemical, cat no. SH75- 125D) and cut into 
40 μm coronal sections using a cryostat (Leica, CM1510). Midbrain 
and striatum sections were immunostained for TH and DAT, using 
methods previously described (Vecchio et al. 2014); TH and the 
noradrenaline transporter (NET) were immunostained in the locus 
coeruleus. Primary antibodies: rabbit anti- TH (1:2000), rat anti- DAT 
(1:200), and anti- NET (1:500; MAb Technologies, cat no. NET05- 2, 
RRID:AB_2571639). Secondary antibodies: anti- rabbit AF680 
(1:4,000), anti- rat IRdye 800 (1:2000), and anti- mouse IRdye 
800CW (1:2000). Slides were scanned using the LiCOR Odyssey 
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system, with a focus offset of 0.90– 1.0 mm. For original scan im-
ages, see https://osf.io/2tqwe/ ?view_only=c9d0d 18722 1c4ca 
989bc 93455 534b98d.
2.6 | Tissue catechol contents
Catecholamines (dopamine, noradrenaline), their respective metabo-
lites (DOPAC, DHPG), and cysteinylated catechols were measured in 
the striatum and in heart tissue, using methods previously described 
(Casida et al. 2014; Goldstein et al. 2013; Wey et al. 2012). Briefly, 
striata were dissected and flash frozen in liquid nitrogen. Frozen tissue 
samples were homogenized in a mixture of 20:80 of 0.2 M phosphoric 
acid: 0.2 M acetic acid. The supernate was assayed by batch alumina 
extraction followed by high- performance liquid chromatography 
(HPLC) with electrochemical detection, using a Spheri- 5 RP- 18, 5 μm, 
30 × 2.6 mm guard column (PerkinElmer, Part No. 07110013) and C18, 
5 µm, 120 Å, 4.6 × 250 mm analytic column (Thomson Instruments, 
Part No. BA400- 046250), on a Waters Model 710B (WISP) automated 
sample processor (Waters Associates). The mobile phase consisted of 
13.8 g monobasic sodium phosphate, 28– 40 mg octanesulfonic acid, 
50 mg EDTA, and 0– 5 ml acetonitrile in 1 L of HPLC- grade water, with 
pH adjusted to 3.2– 3.3 using 85% phosphoric acid.
In a separate set of experiments, a single IP injection of the AADC 
inhibitor NSD- 1015 (100 mg/kg) was administered to prevent the rapid 
conversation of L- 3,4- dihydroxyphenylalanine (L- DOPA) to dopamine 
(Jones, Gainetdinov, Jaber, et al., 1998). Mice were sacrificed by cervi-
cal dislocation 40 min following the injection, at which time the striata 
were dissected and flash frozen in liquid nitrogen. Unilateral striata were 
weighed and homogenized in 40 μL per mg sample of 0.1 M perchlo-
ric acid (HClO4) spiked with both 2,3- dihydroxybenzoic acid (DHBA, 
an internal standard) and 100 ng/ml sodium metabisulphite (Caudle 
et al. 2007; Moron et al. 2000), and then centrifuged 10,000 g for 10 min 
at 4℃. The supernatant was carefully removed and filtered through 
a 0.22- μm membrane (Ultrafree- MC GVWP filters; Millipore, cat no. 
UFC30GV00) by centrifugation at 10,000 g for 2 min at 4℃. Tissue con-
tent analyses were conducted using an AgAgCl-  electrochemical detec-
tor (LC- 4C Amperometric Detector; BASi) set at an oxidizing potential 
of + 0.75 V, and a Hypersil Gold C18 column (150 × 3 mm, particle size 
of 5 μm; Thermo Fisher Scientific). The mobile phase was composed of 
5.99 g monobasic sodium phosphate, 200 μM EDTA, 0.684 g sodium 
chloride, 60 mg octyl sodium sulphate, and 95 ml of methanol in 1 L HPLC- 
grade water (pH 2.43). Analytes were quantified against standard curves 
(Sigma, cat no. D9628) (all chemical standards from Sigma, purity >98%). 
The experimenter was blinded until the point of statistical analyses.
2.7 | Glutathione assay
Glutathione concentrations in the striatum were measured using 
a glutathione assay kit (Cayman, cat no. 703002), and determined 
using the kinetic method. Brains were removed and quickly rinsed 
in ice- cold PBS to remove blood on the exterior of the brain; striatal 
and cortical samples were then dissected and flash frozen in liquid 
nitrogen. The weight of the frozen tissue was taken, and the tissue 
was homogenized in ice- cold MES buffer (0.4 M 2[N- morpholino] 
ethanesulphonic acid, containing 1 mM EDTA; pH 6– 7; 10 μL per mg 
of tissue). Homogenate was spun at 10,000 g for 15 min at 4℃. The 
supernatant was transferred to a clean tube, and deproteinated using 
metaphosphoric acid (MPA) and 4 M triethanolamine (TEAM) solu-
tion, as per kit instructions. A subgroup of wild- type mice were in-
jected with 5 mg/kg of reserpine (injection volume: 0.2 ml/g) 120 min 
prior to dissection, as a positive control of oxidative stress (Spina & 
Cohen, 1989). Reserpine is known to irreversibly block VMAT2, lead-
ing the accumulation of cytosolic dopamine (Bernstein et al. 2014; de 
Freitas et al. 2016). In turn, this can lead to increased metabolism, and 
enzymatic and spontaneous oxidation, and has been shown to induce 
oxidative stress and reduce glutathione in dopaminergic cells (Spina & 
Cohen, 1989). Cortical tissue was used as a negative control.
2.8 | H2O2 assay
H2O2 concentrations in striatal samples were measured as per kit in-
structions (Abcam, cat no. ab102500), using the colorimetric method. 
Briefly, striata were dissected, homogenized in ice- cold buffer, and 
spun for 5 min at top speed (4℃). Supernatant was immediately de-
proteinated using perchloric acid (PCA, 4 M) and potassium hydroxide 
(KOH, 2 M) and samples were spun (15 min, 13,000 g, 4℃), after which 
supernatant was stored at −80℃ until use. In preparation for the 
assay, samples were diluted in assay buffer 1:10, with 50 μl of diluted 
sample added to 50 μl of reaction mix. Plates were read at OD570 nm. 
The experimenter was blinded until the point of statistical analyses.
2.9 | Locomotor activity and 
amphetamine challenge
Experiments began at approximately 8:00 a.m., with mice introduced 
to the experimental room half an hour prior to beginning.
Locomotor activity was measured in automated locomotor activ-
ity monitors (Accuscan Instruments). Baseline gross locomotor activ-
ity was measured for 4 hr, with total distance travelled recorded in 
5- min bins (or epochs). In amphetamine- challenge experiments, out-
put parameters of total distance travelled and stereotypic behaviours 
were collected in 5- min bins over the course of the test period. Mice 
were placed in the activity monitor chamber (20 cm ×20 cm) and 
measured under baseline conditions for 60 min. Following baseline 
recording, mice received an injection of saline or 2 mg/kg or 3 mg/kg 
amphetamine (dissolved in 0.9% wv- 1 saline) and were observed for 
an additional 90 min. All injections were intraperitoneal (IP) at an in-
jection volume of 0.1 ml/g (Salahpour et al. 2008; Vecchio et al. 2014).
We sought to confirm that augmented amphetamine responses 
in TH- HI mice result from increased de novo dopamine synthesis. 
Wild- type and TH- HI mice were separated into two groups each. 
Sixty minutes prior to administration of amphetamine (3.0 mg/kg), 
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one group received a control injection of saline and the other, an 
IP injection of NSD- 1015 (100 mg/kg), blocking the synthesis of de 
novo dopamine. As before, mice were allowed to habituate during 
this time. Locomotor activity was recorded for an additional 90 min 
following the injection of amphetamine. Due to the potential stress 
of the first injection combined with the introduction to the recording 
chambers, the first 15 min following the first injection were excluded 
from analyses of the baseline (pre- amphetamine) period. The experi-
menter was blinded until the point of statistical analyses.
2.10 | Methamphetamine challenge
Adult wild- type and TH- HI mice were randomly assigned to treat-
ment groups that would receive 4 injections of 0.9% saline, 5.0 mg/
kg or 10 mg/kg of (+)- Methamphetamine HCl (Sigma; dissolved in 
0.9% saline). Treatments were administered through a subcutaneous 
injection as previously described (Lohr et al. 2015). The first dose 
was administered 60 min after baseline core body temperature was 
measured using a rectal thermometer. Three additional equivalent 
doses followed, administered at 2- hr intervals (i.e. 180, 300, and 
420 min following the initial injection). Core body temperature was 
measured at the time of each injection. Mice were killed by rapid 
decapitation 48 hr following the first injection, and the striatum was 
dissected and flash- frozen in liquid nitrogen for protein analyses by 
Western blot, using standard methods described above. The experi-
menter was blinded until the point of statistical analyses.
2.11 | Statistical analyses
All statistical analyses were performed for each group by Student's t- 
test, one- way ANOVA, or two- way ANOVA. Post hoc analyses were 
performed using the Bonferroni test, Tukey's test (all pairwise com-
parisons), or the Dunnett's test, as appropriate. The F- test was used 
to verify equal variance. Where there was unequal variance between 
two groups analysed by t- test, a Welch's correction was performed. The 
Shapiro– Wilk test was used to assess normality of all data. Where this 
test revealed that distribution was not normal, t- tests were replaced 
with non- parametric Mann– Whitney tests. The Grubbs test was used to 
identify statistical outliers, which were excluded if found. Significance is 
reported where p < .05. No sample calculations were performed prior 
to testing, but sample sizes were based on previous studies. All statisti-
cal testing was carried out using GraphPad Prism version 9.
3  | RESULTS
3.1 | Production of TH- over- expressing (TH- HI) 
mice
Purified BAC DNA containing the murine Th gene was microinjected 
into the pronucleus of donor oocytes, which were then implanted 
into pseudo- pregnant females yielding 4 transgenic pups. The total 
copy number of the Th gene was determined for all pups born to 
the host mothers using quantitative PCR. A pup carrying 6 total 
copies of the Th gene— 2 endogenous alleles and 4 additional copies 
of Th that resulted from integration of the transgene— was assigned 
as the founder of the TH- HI line (p ≤ .0001, t- test) (Figure 2a). 
Commensurate with a 3- fold increase in gene copy number, Th 
mRNA levels in the midbrain of TH- HI mice were 3 times higher 
than that of wild- type littermates (measured relative to a com-
monly used reference gene, Pgk1; p ≤ .0001, t- test) (Figure 2b).
Transgenic mice did not differ in size or appearance relative to 
sex- and age- matched wild- type littermates, nor did they have ap-
parent differences in general health. Mice did not have difficulties 
breeding or delivering pups, and had an average litter size of 5.2 
pups (breeding pairs were retired at 8– 12 months of age).
3.2 | TH protein expression is increased in 
central and peripheral sites of catecholamine 
production in TH- HI mice
TH- HI mice showed a 3- fold increase in the optical density of TH 
protein in the midbrain (p = .0003, t- test) (Figure 2c, d) and striatum 
(p ≤ .0001, t- test) (Figure 2f, g), revealing that the amount of total 
protein translated is proportional to the observed increase in gene 
copy number and mRNA. There was no change in the level of DAT 
protein between wild- type and TH- HI mice (midbrain: Figure 2e, 
p = .32, t- test; striatum: Figure 2h, p = .80, t- test).
Immunostaining revealed that TH protein was expressed in similar 
patterns in the midbrain and striatum of wild- type and transgenic mice 
(Figure 2j, i). No evidence of ectopic expression of TH was detected 
in the regions that surround the striatum in the forebrain, or the sub-
stantia nigra and ventral tegmental area in the mesencephalon.
To assess protein expression in the noradrenergic system, we quan-
tified total TH protein in the locus coeruleus. There was an approximate 
3- fold increase in TH optical density, comparable to the increase in TH 
observed in dopaminergic regions (p = .0014, t- test) (Figure S1a, b).
Immunostaining showed that TH expression patterns in the locus 
coeruleus of transgenic mice mirrored that of wild- type littermates, 
again without evidence of ectopic expression (Figure S1c).
Peripheral expression of TH was measured in the adrenal me-
dulla, where it is highly concentrated (de Diego et al. 2008). In 
transgenic mice, total TH protein in the adrenal medulla was approxi-
mately 2.5 times higher than that of wild- type littermates (p = .0035, 
t- test) (Figure S1d, e), demonstrating successful overproduction of 
TH in both peripheral and central nervous systems.
3.3 | TH- HI mice have increased levels of 
phosphorylated TH and TH enzymatic activity
Western blot analyses showed an approximate 3- fold increase in the 
optical density of striatal TH phosphorylated at Ser40, Ser31, and 
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F I G U R E  2   Tyrosine hydroxylase over- expressing mice. (a) Genomic copy number of tyrosine hydroxylase (TH) in TH- HI mice relative 
to wild- type (WT) littermates. Copy number is determined by comparison of the cycle threshold to that of the reference gene, Tfrc. (n = 5 
per group; p ≤ .0001, t- test). (b) Th mRNA levels in TH- HI and WT mice, relative to the reference gene Pkg1. All values are normalized to 
dopamine transporter (DAT) mRNA levels in the same sample, which is used as a marker of dopaminergic cells, and shown relative to wild- 
type levels (WT n = 8, TH- HI n = 7; p ≤ .0001, t- test with Welch's correction). (c) Midbrain TH and DAT protein expression is shown in adult 
mice by western blot together with the loading control, Na- KPase (representative samples) (n = 6 per group). (d) Average optical density of 
midbrain TH protein in TH- HI mice (normalized to Na- KPase), shown relative to wild- type mice (p = .0003, t- test with Welch's correction). 
(e) Average optical density of midbrain DAT protein in TH- HI mice (normalized to Na- KPase), shown relative to wild- type mice (p = .34, 
t- test). (f) Striatal TH and DAT protein expression is shown in adult mice by western blot together with the loading control, Na- KPase 
(representative samples) (n = 6 per group). (g) Average optical density of striatal TH protein in TH- HI mice (normalized to Na- KPase), shown 
relative to wild- type mice (p ≤ .0001, t- test). (h) Average optical density of striatal DAT protein in TH- HI mice (normalized to Na- KPase), 
shown relative to wild- type mice (p = .80, t- test). (i) Immunohistochemistry reveals protein expression patterns of TH (red) and DAT (green) 
in the midbrain. Yellow represents co- localized TH and DAT. (j) Protein expression patterns of TH (red) and DAT (green) in the striatum. 
Yellow represents co- localized TH and DAT. n = number of mice. (p < .001, ***) Mean ± SEM
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Ser19, demonstrating that the level of phosphorylated TH increases 
in proportion to total TH protein levels in transgenic mice (Ser40, 
p ≤ .0001, t- test; Fig. S2a, b) (Ser31, p ≤ .0001, t- test; Figure S2d, e) 
(Ser19, p ≤ .0001, t- test; Figure 2g, h). The proportion of TH that was 
phosphorylated relative to the total pool did not significantly differ 
between wild- type and TH- HI mice at any residue (Figure S2c, f, i).
Elevated levels of phosphorylated TH in TH- HI mice indicate that 
the over- expressed enzyme is in an active state, and in a conforma-
tion less susceptible to feedback inhibition by catechols (Daubner 
et al. 2011). In turn, the extent of L- DOPA accumulation in striatal 
samples provides a measure of TH enzymatic activity in vivo (Ferris 
et al. 2014). Therefore, we next assessed striatal levels of L- DOPA, 
the direct product of TH. In TH- HI mice, L- DOPA accumulation 
following injections of NSD- 1015, which blocks aromatic L- amino 
acid decarboxylase (AADC), was twice that in wild- type animals 
(p ≤ .0001, t- test) (Figure 3a). The increase in L- DOPA accumulation 
directly shows that the over- expressed TH protein is functional, in-
creasing the rate of dopamine synthesis 2- fold in TH- HI mice.
3.4 | Striatal dopamine levels and tissue dopamine 
turnover are increased in TH- HI mice
There was a significant effect of genotype on striatal tis-
sue content of dopamine, which rose over wild- type levels by 
approximately 50% (p ≤ .0001, t- test) (Figure 3b). The total tis-
sue content of DOPAC was also elevated by more than 2- fold in 
the TH- HI mice (p ≤ .0001, Mann– Whitney test) (Figure 3c). In 
addition, DOPAC/dopamine ratios were increased in TH- HI mice 
(p ≤ .0001, Mann– Whitney test) (Figure 3d), representative of in-
creased dopamine turnover.
3.5 | VMAT2 levels are unchanged in TH- HI 
transgenic mice
We next sought to determine if the expression of VMAT2 was up- 
regulated in TH- HI mice to accommodate the increased dopamine 
production. There was no difference in VMAT2 protein levels be-
tween TH- HI mice and wild- type littermates (Figure S3).
3.6 | Oxidative stress is enhanced in TH- HI mice
An elevated presence of DOPAC can suggest accelerated ROS pro-
duction, as H2O2 is produced by MAO during the first steps of do-
pamine metabolism; in addition, increased levels of DOPAC could 
be accompanied by an elevated presence of reactive intermediates 
such as DOPAL, as well as increased reactive species as a result of 
metabolic oxidation. Concomitant with increased dopamine produc-
tion and increased dopamine turnover, H2O2 was found to be ele-
vated in the striatum of TH- HI mice by approximately 30% (p = .031, 
t- test) (Figure 4a). In addition, levels of glutathione— which acts to 
neutralize H2O2 — were significantly reduced in the striatum of adult 
TH- HI mice (p = .0019, one- way ANOVA), but not in cortical tissue 
(Figure 4b, c).
Wild- type mice were treated with reserpine (5 mg/kg) as a 
positive control. Reserpine acts by irreversibly blocking VMAT2, 
in turn inhibiting the transport of catecholamines from the cytosol 
to the vesicles, leading to oxidative stress and reduced glutathione 
levels (de Freitas et al. 2016; Spina & Cohen, 1989). As expected, 
reserpine treatment of WT animals results in reduced glutathione 
levels (Figure 4b). Importantly, the extent of decrease in glutathi-
one levels of reserpine treated WT animals was similar to the basal 
levels detected in TH- HI (Figure 4b), which is consistent with an 
elevated presence of ROS in regions where increased TH activity 
is observed.
3.7 | TH- HI mice have elevated striatal levels of 
enzymatic and spontaneous oxidation products
TH- HI mice had elevated striatal levels of the reactive intermediate 
metabolite DOPAL compared with wild- type mice (p = .010, t- test) 
(Figure 4d), resulting from increased enzymatic oxidation. Cysteinyl- 
L- DOPA and cysteinyl- dopamine were also elevated in TH- HI ani-
mals compared with wild- type littermates (p = .0003 and p = .0002, 
respectively, t- test) (Figure 4e, f). As an increased presence of 
F I G U R E  3   Synthesis and tissue content of dopamine and 
its metabolites in the striatum of adult mice. TH- HI mice show 
elevated tissue content of (a) L- DOPA accumulation following 
NSD- 1015 injections (WT n = 7, TH- HI n = 7; p ≤ .0001, t- test), 
(b) dopamine (DA) (WT n = 10, TH- HI n = 9; p ≤ .0001, t- test), (c) 
3,4- dihydroxyphenylacetic acid (DOPAC) (WT n = 10, TH- HI n = 9; 
p ≤ .0001, Mann– Whitney test), and (d) DOPAC to DA ratio (WT 
n = 10, TH- HI n = 9; p ≤ .0001, Mann– Whitney test). n = number of 
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cysteinylated dopamine is considered an indication of accelerated 
dopamine auto- oxidation (Chen et al. 2008; Li & Dryhurst, 2001), 
these findings demonstrate that increased activity of TH alone is 
sufficient to elevate markers of oxidative stress arising from enzy-
matic and spontaneous oxidation.
3.8 | TH- HI mice have increased cardiac levels of 
dopamine and its oxidation products
Past studies have suggested that catecholamine dysfunction 
and denervation of the heart may occur early in the pathology of 
Parkinson's disease, preceding the onset of recognizable motor 
symptoms (Goldstein et al. 2007). To examine whether markers of 
oxidative stress exist in peripheral tissue, we examined catechola-
mine content, catecholamine turnover, and cysteinylated catechols 
in heart tissue. TH- HI mice had increased cardiac concentrations of 
dopamine (p ≤ .0001, Mann– Whitney test) and DOPAC (p = .0002, 
Mann– Whitney test). There was a trend towards increased dopa-
mine turnover (p = .054, t- test) (Figure S4a- c). In addition, there was 
a significant increase in Cys- DA (p = .0042, Mann– Whitney test) 
(Figure 3g). There were no group differences in levels of noradrena-
line or its metabolite DHPG (Figure S4d– f). DOPAL was not detected 
in any samples of heart tissue.
3.9 | TH- HI mice have potentiated responses to 
amphetamine
The locomotor behaviour of transgenic mice was not found to differ 
from their wild- type littermates when measured for up to 4 hr under 
normal (unstimulated) conditions (Figure 5a); similar results were 
found during baseline recordings prior to an amphetamine challenge 
(see minutes 0– 60, Figure 5b).
As a functional read- out of enhanced dopamine production 
and storage, we challenged mice with two doses of amphetamine 
(2.0 mg/kg and 3.0 mg/kg). Amphetamine treatment results in mas-
sive efflux of monoamines through their membrane transporters 
due to a reversal in the concentration gradient (Heal et al. 2013; 
Jones et al. 1998; Salahpour et al. 2008; Sulzer et al. 1995). Because 
of its potent effect on the dopaminergic system, amphetamine is 
often used to test the integrity of the nigrostriatal pathway, using 
locomotor activity as an outcome measure (Giros et al. 1996). When 
challenged with these two doses of amphetamine (2.0 mg/kg and 
3.0 mg/kg), TH- HI mice had a greatly potentiated locomotor re-
sponse to amphetamine, more than doubling total distance trav-
elled in the 90 min (Figure 5b, c). In addition, TH- HI mice showed 
increased stereotypic behaviour in response to the drug, increasing 
their stereotypic counts 2- fold following the administration of am-
phetamine at both doses (Figure 5c).
F I G U R E  4   Markers of oxidative stress in adult TH- HI mice. (a) Concentration of hydrogen peroxide was found to be elevated in striatal 
tissue of adult transgenic mice (TH- HI) as compared with wild- type (WT) littermates (WT n = 8, TH- HI n = 9)(p = .031, t- test). (b) Total 
glutathione levels (GSH) were reduced in striatal tissue of TH- HI mice compared with WT mice. No significant difference in striatal GSH 
levels was detected between transgenic mice and WT mice that had been treated with reserpine 120 min prior to dissections (WTres). (WT 
n = 14; TH- HI n = 14; WTres n = 7) (all data normalized to WT) (F2, 32 = 7.709, p = .0019, one- way ANOVA, Bonferroni post hoc). (c) No 
change in GSH levels was detected in cortical samples. (WT n = 14; TH- HI n = 14; WTres n = 7) (all data normalized to WT) (F2, 33 = 1.647, 
p = .21, one- way ANOVA, Bonferroni post hoc). (d) 3,4- dihydroxyphenylacetaldehyde (DOPAL) levels in the striatum of TH- HI mice were 
elevated over wild- type levels (WT n = 10, TH- HI n = 9)(p = .010, t- test), as were (e) Cysteinylated L- 3,4- dihydroxyphenylalanine (Cys- DOPA) 
levels (WT n = 10, TH- HI n = 9) (p = .0003, t- test with Welch's correction) and (f) Cysteinylated dopamine (Cys- DA) levels (WT n = 10, TH- HI 
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The potentiation in amphetamine- induced hyperactivity was not 
associated with alterations in dopamine D1 or D2 receptor levels in 
TH- HI mice (Figure 5e, f).
3.10 | Responses to amphetamine depend on 
dopamine synthesis
We next sought to confirm that the elevated amphetamine response 
seen in TH- HI mice resulted from de novo dopamine synthesis by 
using NSD1015, which blocks AADC. Administration of NDS- 1015 
had a significant drug effect, even during the pre- amphetamine ha-
bituation phase (p = .013, two- way ANOVA) (Figure S5a, b). In par-
ticular, during this habituation phase, TH- HI mice that had received 
NSD- 1015 demonstrated reduced locomotor activity as compared 
with those that had received saline (p ≤ .05, Tukey's multiple com-
parisons post hoc t- test).
Wild- type and TH- HI mice that had received NSD- 1015 did not 
have a hyperactive response to amphetamine. After receiving an 
amphetamine challenge, total distance travelled by wild- type mice 
that had received an NSD- 1015 pre- treatment was reduced by 77% 
of that travelled by wild- type mice that had received saline (p < .01, 
Tukey's multiple comparisons post hoc t- test). Distance travelled by 
TH- HI mice that had received NSD- 1015 was reduced by 97% of the 
distance travelled by TH- HI mice that had received the saline pre- 
treatment (p < .0001, Tukey's multiple comparisons post hoc t- test) 
(Figure S5b).
3.11 | TH- HI mice show increased sensitivity to 
methamphetamine toxicity
We next tested the sensitivity of TH- HI mice to methamphetamine 
toxicity. At doses of 5.0 mg/kg or 10 mg/kg, there was no difference 
in the hyperthermic response to methamphetamine between adult 
TH- HI mice and wild- type littermates (Figure 6a). At 48 hr after in-
traperitoneal injection of 5.0 mg/kg methamphetamine, mean DAT 
striatal protein levels were reduced by 62.2% in wild- type mice and 
67.0% in TH- HI mice relative to saline- treated wild- type controls 
(Figure 6b, c). In response to 10 mg/kg, DAT levels were reduced 
by 65.2% in wild- type mice and 79.7% in TH- HI compared with DAT 
levels of saline- treated wild- type mice. The TH- HI group had greater 
sensitivity to methamphetamine than their wild- type littermates at 
the 10 mg/kg dose (p ≤ .05, two- way ANOVA).
F I G U R E  5   Locomotor response to amphetamine. (a) Baseline locomotor behaviour over 240 min, measured as total distance travelled 
(cm) in 5- min epochs. (Repeated- measures two- way ANOVA: effect of time, F47, 987 = 65.20, p ≤ .0001; effect of genotype, F1,987 = 0.39, 
p = .54; genotype x drug interaction, F47, 987 = 1.76, p ≤ .0015; Bonferroni post hoc) (WT n = 12, TH- HI n = 11). (b) Total distance travelled 
in 5- min epochs, before and after injection with 3.0 mg/kg amphetamine (arrow denotes time of injection). (Repeated- measures two- way 
ANOVA: effect of time, F29,290 = 20.33, p ≤ .0001; effect of genotype, F1,290 = 9.83, p = .011; genotype x drug interaction, F29,290 = 5.49, 
p ≤ .0001) (WT n = 6, TH- HI n = 6). (c) Total distance travelled in 90 min after injection of saline (Two- way ANOVA: effect of drug, 
F2,39 = 35.36, p ≤ .0001; effect of genotype, F1,39 = 28.45, p ≤ .0001; genotype x drug interaction, F2,39 = 6.625, p = .0033; Bonferroni 
post hoc) (saline: WT n = 6, TH- HI n = 6; 2.0 mg/kg: WT n = 13, TH- HI n = 8; 3 mg/kg: WT n = 6, TH- HI n = 6). (d) Total stereotypic counts 
in 90 min after injection of saline, 2.0 mg/kg, or 3.0 mg/kg amphetamine (multiple Mann– Whitney tests with the two- stage Benjamini, 
Krieger, and Yekutieli procedure) (saline: WT n = 6, TH- HI n = 6; 2.0 mg/kg: WT n = 13, TH- HI n = 8; 3 mg/kg: WT n = 6, TH- HI n = 6). (e) 
Quantification of striatal D1 receptors by radioligand binding (n = 4 per group; p = .63, t- test). (f) Quantification of striatal D2 receptors by 
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4  | DISCUSSION
Here we report that directly increasing TH activity in transgenic 
mice augments dopamine turnover and produces markers of oxida-
tive stress in the striatum including elevated levels of H2O2, associ-
ated with accumulation of the autotoxic catecholamine metabolites 
DOPAL and Cys- DA. Increased dopamine production also results in 
increased susceptibility to amphetamine- induced hyperactivity and 
methamphetamine toxicity. These findings suggest that a loss of TH 
regulation could be one factor contributing to mounting oxidative 
stress in early- stage pathologies that is specific to catecholamine 
neurons.
TH- HI mice had a 3- fold increase in both mRNA and total TH 
protein levels (Figure 2c,d, f, g). In addition, transgenic mice had 
approximately 3 times the levels of phosphorylated TH (Figure S2) 
and increased rates of TH activity compared with age- matched 
littermates (Figure 3a). Phosphorylation of TH directly influences 
the rate of catecholamine synthesis by inducing a conformational 
change that releases the enzyme from end- product inhibition— a 
state in which a newly synthesized catechol is bound to ferric (Fe3+) 
iron in the active site of TH following a hydroxylation reaction. In 
turn, unbinding of catechols allows the iron molecule to be reduced 
to its ferrous (Fe2+) form, returning TH to an active state and free-
ing the iron molecule for further interactions (Dunkley et al. 1996; 
Haavik, 1997; Haavik et al. 1997). Our findings show that TH- HI mice 
have a significant increase in the levels of active- state TH compared 
with their non- transgenic littermates, in turn leading to increased 
dopamine production.
In TH- HI mice, the proportionate increase in striatal DOPAC 
content exceeded that of dopamine, indicating an increased rate of 
intracellular dopamine turnover (Figure 3d) (Gemechu et al. 2018). 
Under normal circumstances, the majority of the catecholamine 
pool is stored in vesicles, rendering it available for release upon 
neuronal stimulation and protecting the cell from oxidative pro-
cesses that could be damaging (Pifl et al. 2014; Taylor et al. 2014; 
Vernon, 2009). Increased VMAT2 levels have been shown to 
lead to increased size and filling of presynaptic vesicles (Lohr 
et al. 2014, 2015), and thus, an up- regulation in VMAT2 expres-
sion could reflect a strategy by which cells might mitigate damage 
induced by an increased presence of monoamines in the cytosol. 
TH- HI mice did not differ from wild- type littermates in VMAT2 
levels (Figure S3) and therefore may not have compensated ad-
equately for the increase in dopamine production. Consistent 
with this finding, TH- HI mice showed an increase in striatal H2O2 
concomitant with decreased striatal glutathione and increased 
DOPAL content (Figure 4).
A recent study by Bucher et al. (2020) that examined the crit-
ical role of VMAT2 in maintaining dopamine homeostasis further 
emphasizes the toxicity of rising levels of cytosolic dopamine. An 
adeno- associated virus was used to introduce small- hairpin RNA 
F I G U R E  6   Toxicity of methamphetamine. (a) Measurements of the core body temperature of animals administered with saline, 5 mg/kg 
or 10 mg/kg of methamphetamine revealed no difference in the effect of treatment between genotypes. (p ≤ .05, *; p ≤ .01, **; p ≤ .001, ***, 
repeated- measures two- way ANOVA) (WT: saline n = 7, 5 mg/kg n = 7, 10 mg/kg n = 6; TH- HI: saline n = 5, 5 mg/kg n = 7, 10 mg/kg n = 6). 
(b) Representative blot, showing striatal DAT protein levels in WT and TH- HI mice, (n = 2 of 4 shown per treatment group). (c) Striatal DAT 
protein levels relative to level seen in WT mice treated with saline, after administration of saline, 5 mg/kg or 10 mg/kg methamphetamine. 
(effect of genotype, ns; effect of dose, F2, 19 = 255.4, p ≤ .0001; genotype × dose interaction, F2, 19 = 3.59, p = .048; two- way ANOVA) 
(Bonferroni post hoc, p = .025, *) n = number of mice. Mean ± SEM
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interference of endogenous VMAT2 in adult rats, resulting in a pro-
gressive adult- onset loss of VMAT2 and accumulation of unseques-
tered dopamine. The disruption resulted in a subsequent increase 
in dopamine metabolism, behavioural deficits and degeneration of 
nigrostriatal neurons— consequences that were rescued through the 
reintroduction of VMAT2 (Bucher et al. 2020). These results show 
that dysregulation of dopamine homeostasis acquired in adulthood 
is sufficient to produce dopamine toxicity in the nigrostriatal path-
way (Bucher et al. 2020).
Dopamine dysregulation can promote cytotoxicity due to 
the potential for oxidation (Caudle et al. 2007; Chen et al. 2008; 
Hastings et al. 1996; Masoud et al. 2015; Mosharov et al. 2009; 
Taylor et al. ,2009, 2014). DOPAL and H2O2 are formed as a result 
of the enzymatic metabolism of dopamine (Goldstein et al. 2013; 
Spina & Cohen, 1989). DOPAL itself also spontaneously oxidizes 
forming DOPAL- quinones, and in the process generates superox-
ide radicals. These radicals are believed to contribute to DOPAL- 
induced oligomerization of α- synuclein (Werner- Allen et al. 2017), 
impede vesicular functions (Plotegher et al. 2017), and damage 
mitochondrial function (Sarafian et al. 2019). DOPAL- quinones are 
capable of forming protein adducts with α- synuclein and other in-
tracellular proteins, which can in turn initiate cytotoxic processes 
(Jinsmaa et al. 2018).
In addition to producing damaging compounds through the 
process of metabolism, unsequestered dopamine and related com-
pounds are susceptible to spontaneous oxidation, forming ROS 
and dopamine- quinones. Dopamine- quinones— which are electron- 
deficient— can then react with reduced sulfhydryl groups such as 
free cysteine or glutathione, or covalently bind to cysteine groups 
on nucleophilic proteins (often at the active site), which can impair 
their function and have detrimental effects on the cell (Goldstein 
et al. 2016, 2017; Hastings et al. 1996; Hastings & Zigmond, 1994). 
Therefore, the presence of cysteinylated catechols is used as a mea-
sure of the oxidation of free cytosolic dopamine (Caudle et al. 2007; 
Chen et al. 2008; Masoud et al. 2015). TH- HI mice had elevated lev-
els of DOPAL as well as increased levels of cysteinyl- L- DOPA and 
cysteinyl- dopamine (Figure 4), providing evidence of both enzymatic 
and spontaneous oxidation (Figure S6) (Chen et al. 2008; Fornstedt 
et al. 1989, 1990; Fornstedt & Carlsson, 1989; Hastings et al. 1996).
Recent studies suggest a critical link between unsequestered 
catecholamines and α- synuclein aggregation, leading to toxicity. 
Alpha- synuclein oligomers have been shown to be kinetically sta-
bilized by oxidized dopamine and other catecholamines in vitro 
(Conway et al. 2001; Mor et al. 2017; Norris & Giasson, 2005; 
Norris et al. 2005). Mor et al. (2017) reported that chronic eleva-
tion of dopamine levels in α- synuclein A53T mice results in pro-
gressive nigrostriatal degeneration and locomotor impairment, to 
an extent not seen in A53T mice alone, demonstrating a synergistic 
toxicity of dopamine and α- synuclein. Dopamine was also shown 
to modify α- synuclein aggregation in vivo, forming oligomers that 
share biochemical and structural characteristics with neurotoxic 
α- synuclein oligomers produced by interactions with dopamine 
in vitro (Mor et al. 2017). In another study, Burbulla et al. (2017) 
causally linked lysosomal dysfunction and α- synuclein accumu-
lation to elevated levels of oxidized dopamine in the cytosol, in a 
dopamine- dependent "toxic cascade," using dopamine neurons de-
rived from Parkinson's patients (Burbulla et al. 2017). In cultured 
human oligodendrocytes and PC12 rat pheochromocytoma cells, 
Jinsmaa et al. demonstrated that DOPAL is even more potent than 
dopamine in producing quinones and protein modifications, includ-
ing the oligomerization of α- synuclein. Notably, treatment with the 
antioxidant N- acetylcysteine— a precursor of glutathione— reduced 
DOPAL- quinone formation, in turn attenuating or preventing all as-
sociated protein modifications (including α- synuclein oligomeriza-
tion) (Jinsmaa et al. 2018).
TH- HI mice also showed an increase in the hyperactive response 
to amphetamine (Figure 5). This response was dependent on de novo 
dopamine synthesis (Supp. Figure 5). Amphetamine releases dopa-
mine from vesicles and causes a rapid efflux of cytosolic dopamine 
into the extracellular space due to backward transport through the 
cell membrane dopamine transporter (Masoud et al. 2015; Takahashi 
et al. 1997). Similarly, methamphetamine can redistribute dopamine 
from intraneuronal storage sites and in this way is believed to result 
in increased dopamine auto- oxidation and dopamine terminal injury 
(Fumagalli et al. 1998). Our finding that TH- HI mice had augmented 
sensitivity to methamphetamine toxicity is consistent with an ad-
ditive effect on an already- elevated basal state of oxidative stress 
(Figure 6).
How an increase in TH activity might specifically contribute to 
oxidative stress in vivo is of particular relevance, as past studies 
have shown diminished TH regulation to coincide with other patho-
logical change, such as increased α- synuclein aggregation (Alerte 
et al. 2008; Farrell et al. 2014; Greenwood et al. 1991; Liu et al. 2015; 
Liu, Zhang, et al., 2008; Locke et al. 2008; Lou et al. 2010; Walker 
et al. 2013; Zhou et al. 2011). Although Parkinson's disease and 
ageing are associated with dopaminergic cell loss— and thus, a loss 
of TH- positive cells— past studies showed that in C57BL mice aged 
104 weeks, striatal DA and DOPAC contents were 5– 7 times higher 
in surviving TH- positive substantia nigra pars compacta neurons 
compared with those in 8- week- old mice, suggesting that surviving 
neurons compensate for the neuronal loss by increasing dopamine 
synthesis (Greenwood et al. 1991). Similar results have been seen in 
MPTP- treated mice, where there is a compensatory increase in TH 
activity in the remaining individual surviving neurons (Greenwood 
et al. 1991; Kozina et al. 2014). Therefore, particularly as other pa-
thologies emerge, it is possible that TH might contribute to mounting 
oxidative stress if activity is considered at the level of the cell.
TH- HI mice may be a useful model for further investigating 
catecholamine autotoxicity in the context of Parkinson's disease, 
particularly as it relates to α- synuclein modifications and dopami-
nergic cell death. First, oxidation products are known to stabilize 
α- synuclein oligomers (Conway et al. 2001; Mor et al. 2017), which 
have a diminished ability to regulate TH activity (Hua et al. 2015; 
Lou et al. 2010; Park et al. 2016; Peng et al. 2005; Wu et al. 2011). 
Therefore, it is possible that the products of spontaneous and 
metabolically oxidized dopamine in turn impede the regulation of 
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dopamine production, producing a pathogenic cycle that further 
facilitates dopamine dysregulation. Second, DOPAL- induced pro-
tein modifications such as α- synuclein oligomerization can in turn 
impede vesicular functions, which may lead to increased levels of 
cytosolic dopamine (Goldstein, 2020; Masato et al. 2019; Plotegher 
et al. 2017). Again, this could result in the genesis of a cytotoxic cycle. 
Many recent studies have indeed suggested that oxidized dopamine 
and α- synuclein oligomers are together engaged in pathogenesis 
and the degeneration of dopaminergic cells (Burbulla et al. 2017; Lou 
et al. 2010; Mor et al. 2017; Qu et al. 2018), and such pathways could 
be explored in future studies using TH- HI mice.
In conclusion, directly increasing TH activity alone is sufficient to 
produce markers of oxidative stress, such as increased striatal H2O2 
and a decreased glutathione level. TH- HI mice have neurochemical 
evidence for increases in both enzymatic and spontaneous oxidation 
of cytoplasmic dopamine, as indicated by increased levels of DOPAL 
and 5- S- cysteinyldopamine. Altered TH regulation due to age or 
early- stage pathologies could be one factor contributing to mount-
ing oxidative stress, and support further studies of TH as a potential 
contributor to catecholamine dysregulation.
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